Metabolisches Syndrom und Prostatakarzinom

详细信息    查看全文

• 作者：Prof. Dr. B.J. Schmitz-Dr?ger (1) <br> G. Lümmen (2) <br> E. Bismarck (1) <br> C. Fischer (3) <br>
• 关键词：Prostatakrebs ; übergewicht ; Diabetes ; Cholesterin ; Hormontherapie ; Prostate cancer ; Obesity ; Diabetes ; Cholesterol ; Hormone therapy
• 刊名：Der Urologe A
• 出版年：2013
• 出版时间：June 2013
• 年：2013
• 卷：52
• 期：6
• 页码：842-846
• 全文大小：303KB
• 参考文献：1. Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med 15:539-53 CrossRef <br> 2. NCEP (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486-497 CrossRef <br> 3. World Health Organization (1999) Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO Consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneva, Switzerland: World Health Organization. http://whqlibdoc.who.int/hq/1999/WHO_NCD_NCS_99.2.pdf. Zugegriffen:12. Dec 2003 <br> 4. Alberti KG, Zimmet P, Shaw J (2006) Metabolic syndrome -a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med 23:469-68 CrossRef <br> 5. Qiao Q, DECODE Study Group (2006) Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women. Diabetologia 49:2837-846 CrossRef <br> 6. Chu DI, Freedland SJ (2011) Metabolic risk factors in prostate cancer. Cancer 117:2020-023 CrossRef <br> 7. Elovainio M, Ferrie JE, Singh-Manoux A et al (2011) Socioeconomic differences in cardiometabolic factors: social causation or health-related selection? Evidence from the Whitehall II Cohort Study, 1991-004. Am J Epidemiol 174:779-89 CrossRef <br> 8. Liang Y, Ankerst DP, Sanchez M et al (2010) Body mass index adjusted prostate-specific antigen and its application for prostate cancer screening. Urology 76:1268 <br> 9. De Nunzio C, Aronson W, Freedland SJ et al (2012) The correlation between metabolic syndrome and prostatic diseases. Eur Urol 61:560-70 CrossRef <br> 10. Morote J, Ropero J, Planas J et al (2012) Metabolic syndrome increases the risk of aggressive prostate cancer detection. BJU Int, doi: 10.1111/j.1464-410X.2012.11406.x <br> 11. Van Hemelrijck M, Garmo H, Holmberg L et al (2011) Prostate cancer risk in the Swedish AMORIS study: the interplay among triglycerides, total cholesterol, and glucose. Cancer 117:2086-095 CrossRef <br> 12. Waters KM, Henderson BE, Stram DO et al (2009) Association of diabetes with prostate cancer risk in the multiethnic cohort. Am J Epidemiol 169:937-45 CrossRef <br> 13. Rodriguez C, Patel AV, Mondul AM et al (2005) Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol 161:147-52 CrossRef <br> 14. Ma J, Li H, Giovannucci E et al (2008) Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 9:1039-047 CrossRef <br> 15. Gong Z, Neuhouser ML, Goodman PJ et al (2006) Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 15:1977-983 CrossRef <br> 16. Libby G, Donnelly LA, Donnan PT et al (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32:1620-625 CrossRef <br> 17. Wright JL, Stanford JL (2009) Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control 20:1617-622 CrossRef <br> 18. Miao Jonasson J, Cederholm J, Eliasson B et al (2012) HbA1C and cancer risk in patients with type 2 diabetes -a nationwide population-based prospective cohort study in Sweden. PLoS One 7:38784 CrossRef <br> 19. Azoulay L, Dell’Aniello S, Gagnon B et al (2011) Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol Biomarkers Prev 20:337-44 CrossRef <br> 20. Teppala S, Shankar A (2010) Association between serum IGF-1 and diabetes among U.S. adults. Diabetes Care 33:2257-259 CrossRef <br> 21. Rowlands MA, Gunnell D, Harris R et al (2009) Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer 124:2416-429 CrossRef <br> 22. Rowlands MA, Holly JM, Gunnell D et al (2012) Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT. Cancer Res 72:503-15 CrossRef <br> 23. Freedland SJ, Wen J, Wuerstle M et al (2008) Obesity is a significant risk factor for prostate cancer at the time of biopsy. Urology 72:1102-105 CrossRef <br> 24. Freedland SJ, Banez LL, Sun LL et al (2009) Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database. Prostate Cancer Prostatic Dis 12:259-63 CrossRef <br> 25. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625-638 CrossRef <br> 26. Platz EA, Till C, Goodman PJ et al (2009) Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 18:2807-813 CrossRef <br> 27. Hamilton RJ, Freedland SJ (2008) Review of recent evidence in support of a role for statins in the prevention of prostate cancer. Curr Opin Urol 18:333-39 b013e3282f9b3cc">CrossRef <br> 28. Platz EA, Leitzmann MF, Rifai N et al (2005) Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev 14:1262-269 CrossRef <br> 29. Roddam AW, Allen NE, Appleby P, Key TJ (2008) Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 100:170-83 CrossRef <br> 30. Post JM, Beebe-Dimmer JL, Morgenstern H et al (2011) The metabolic syndrome and biochemical recurrence following radical prostatectomy. Prostate Cancer 2011:245642 CrossRef <br> 31. Saylor PJ, Smith MR (2010) Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer. J Natl Compr Canc Netw 8:211-23 <br> 32. Basaria S, Muller DC, Carducci MA et al (2006) Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 106:581-88 CrossRef <br> 33. Flanagan J, Gray PK, Hahn N et al (2011) Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer. Ann Oncol 22:801-07 CrossRef <br> 34. Hammarsten J, H?gstedt B (2005) Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 41:2887-895 CrossRef <br> 35. Lubik AA, Gunter JH, Hendy SC et al (2011) Insulin increases de novo steroidogenesis in prostate cancer cells. Cancer Res 71:5754-764 CrossRef <br>
• 作者单位：Prof. Dr. B.J. Schmitz-Dr?ger (1) <br> G. Lümmen (2) <br> E. Bismarck (1) <br> C. Fischer (3) <br><br>1. Urologie, EuromedClinic, Europa-Allee 1, 90763, Fürth, Deutschland <br> 2. Urologische Abteilung, St. Josef-Hospital, Troisdorf, Deutschland <br> 3. Urologische Klinik, Klinikum Hohe Warte, Bayreuth, Deutschland <br>
• ISSN：1433-0563

文摘

The relationship between metabolic syndrome (MS) and prostate cancer (PCA) is highly complex and harbors multiple facets not least because MS is not a single entity but represents a poorly defined inhomogeneous mixture of different diseases and conditions. Although numerous studies suggest a correlation between MS or components of MS and the development of prostate cancer, current evidence cannot be considered convincing. While diabetes appears to be inversely related to PCA, increased serum levels of triglycerides, cholesterol and insulin-like growth factor 1 (IGF-1) may be predictive for high grade disease. Further studies suggested that MS and high serum insulin levels are independent predictors of an unfavorable prognosis in patients with metastatic PCA. Early detection and improved therapeutic options have dramatically prolonged the course of the disease in advanced PCA through the last decades. As a consequence, development of MS in patients undergoing hormone therapy along with the cardiovascular risks has gained increasing relevance. Based on this evolution prevention, early detection and sustainable therapy represent an important clinical challenge to modern urologists active in urooncology.